Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ascend Medical vs Spry

Ascend Medical
Graded #426

Lower grade

vs+0.8999999999999986
Spry
Graded #409

Higher grade

The verdict

Spry takes it — 56.8/100 to 55.9/100, but only just.

Spry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo). Ascend Medical is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +9
45
54
Dose & formulationSpry +24
40
64
Clinical oversightAscend Medical +30
85
55
Labs & monitoringAscend Medical +10
62
52
FulfillmentSpry +2
59
61
Contract termsSpry +14
41
55
Ascend Medical · left barSpry · right bar

The numbers

MetricAscend MedicalSpry
WeighScore55.9/10056.8/100
GradeCC
Scorecard rank#426#409
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
Coverage2 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ascend Medical

Graded #426 · C

Strengths

  • Whole-person virtual primary care that includes a medical weight loss program
  • Staffed by licensed MDs, DOs, NPs and PAs
  • Integrates weight loss with primary, mental health and diabetes care
  • Clear state availability (Georgia and Texas)

Where it loses points

  • Available only in Georgia and Texas
  • Specific GLP-1 medications and branded-vs-compounded status not published
  • No pricing disclosed on public pages
  • Weight loss is one service among many, not a dedicated GLP-1 specialist
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard